Emergent Biosolutions (NYSE:EBS) SVP Sells $25,200.00 in Stock

Emergent Biosolutions Inc. (NYSE:EBS) SVP Paul Anthony Williams sold 3,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the transaction, the senior vice president owned 159,098 shares in the company, valued at $1,336,423.20. This represents a 1.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Performance

Shares of Emergent Biosolutions stock opened at $8.29 on Friday. Emergent Biosolutions Inc. has a one year low of $5.61 and a one year high of $14.06. The firm has a market capitalization of $427.51 million, a price-to-earnings ratio of -29.59 and a beta of 2.34. The business has a 50-day simple moving average of $8.36 and a 200 day simple moving average of $9.64. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.29 and a quick ratio of 2.08.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.The business had revenue of $156.10 million for the quarter, compared to the consensus estimate of $145.00 million.

Wall Street Analyst Weigh In

EBS has been the subject of several research reports. UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. HC Wainwright dropped their price objective on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $12.00.

Hedge Funds Weigh In On Emergent Biosolutions

Several hedge funds have recently modified their holdings of EBS. Millennium Management LLC grew its holdings in shares of Emergent Biosolutions by 68.9% in the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after acquiring an additional 1,020,582 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Emergent Biosolutions by 12.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock worth $5,301,000 after acquiring an additional 121,583 shares during the period. Legal & General Group Plc purchased a new position in Emergent Biosolutions in the second quarter worth $31,000. Rhumbline Advisers boosted its position in Emergent Biosolutions by 862.4% in the second quarter. Rhumbline Advisers now owns 84,025 shares of the biopharmaceutical company’s stock worth $536,000 after purchasing an additional 75,294 shares during the last quarter. Finally, Jump Financial LLC bought a new position in Emergent Biosolutions in the 2nd quarter valued at $352,000. Institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.